AI-backed imaging and care coordination firm Viz.ai is partnering with biotechnology firm Regeneron and biopharmaceutical firm Sanofi to deploy and examine an AI-enabled workflow software for COPD.
Viz.ai affords a care coordination platform with greater than 50 FDA-cleared algorithms that assist analyze medical imaging knowledge to offer insights into prognosis, streamline workflows and help with remedy choices.
The corporate affords AI-enabled neurology, trauma, cardiology, radiology and vascular care instruments.
By the partnership, Sanofi and Regeneron will help the corporate’s investigation of its Viz COPD Module, which employs AI and digital well being file knowledge, utilizing pure language processing to detect and handle high-risk COPD sufferers.
COPD is a typical lung illness that causes harm to the lungs and may end up in restricted airflow and respiratory issues.
“At Sanofi, we’re excited to collaborate with Viz.ai to additional tackle unmet wants in COPD care by leveraging AI,” Dr. Paul Rowe, ATSF and head of medical and specialty care at Sanofi, stated in a press release.
“With this collaboration, we are going to examine the influence of the Viz COPD module, a streamlined AI-enabled EHR workflow to enhance entry to care and in the end affected person outcomes in COPD, a illness that is still under-prioritized, underfunded and undertreated compared to different noncommunicable ailments.”
THE LARGER TREND
Earlier this yr, Viz.ai introduced a collaboration with oncology-focused biotech firm Guardant Well being to make use of AI and genomics to deal with challenges in lung most cancers care.
In 2024, Viz.ai introduced a collaboration with Microsoft to supply its AI fashions via the tech large’s Precision Imaging Community, a part of Microsoft Cloud for Healthcare. The partnership, aimed toward enhancing medical workflows for radiologists, noticed greater than 48 AI fashions built-in into Microsoft’s platform.
The corporate additionally introduced quite a few different collaborations, together with alliances with coronary heart assault prediction startup Cleerly and the Addario Lung Most cancers Medical Institute, a nonprofit group that performs lung most cancers analysis.
In 2023, Viz.ai signed a multiyear settlement with international pharmaceutical firm Bristol Myers Squibb to launch an AI-enabled algorithm and software program for supplier workflow dubbed Viz HCM.
In 2022, Viz.ai secured $100 million in Sequence D funding, bringing its valuation to $1.2 billion. The funding got here one yr after the corporate closed its Sequence C funding spherical value $71 million.
